Condition: Safety · Tolerability · Efficacy · Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Jinmin Yu, Doctor · +86-521-67626971 · sdyujinming@126.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital of Shandong First Medical University | Jinan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06639256